Investors are paying attention to EW stock because of the exciting opportunities in structural heart treatments after the company sold its Critical Care division.
Edwards Lifesciences has announced that all of its product categories, including TAVR, TTMT, and surgical structural heart, have made significant contributions to their success.
While the revenue and earnings per share (EPS) for Edwards Lifesciences (EW) provide insight into its performance for the quarter ending December 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.
A positive trend in hospital admissions, increased use of transcatheter heart valves, and a rise in the number of procedures are likely to have benefited EW in the fourth quarter.
Investors should closely monitor Edwards (EW) stock due to recent changes in the options market.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you experienced a loss from your investment in Edwards Lifesciences Corporation (NYSE:EW) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116540&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you experienced a loss from your investment in Edwards Lifesciences Corporation (NYSE:EW) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116519&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you experienced a loss from your investment in Edwards Lifesciences Corporation (NYSE:EW) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116460&wire=1 or reach out to Joseph E. Levi, Esq.
Edward Lifesciences shows strong potential in the field of Structural heart and has a solid long-term plan, which gives reasons to be hopeful.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you experienced a loss from your investment in Edwards Lifesciences Corporation (NYSE:EW) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116381&wire=1 or reach out to Joseph E. Levi, Esq.